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■ Abstract
Objective: To study the effect of seasons on the health-related quality of life (HRQL) of asthmatic children.
Methods: Four groups of asthmatic children 7 to 14 years old were recruited by pediatricians during each season of the year. Their HRQL 
was assessed by means of the Paediatric Asthma Quality of Life Questionnaire (PAQLQ). Other factors surveyed were asthma severity, atopy, 
medical treatment, immunotherapy, obesity, parental smoking, and anti-allergic measures.
Results: The mean (SD) overall PAQLQ score was highest in summer at 6.2 (1.0) and lowest in autumn at 5.5 (1.2). The same trend was found 
for domains in summer and autumn, respectively: symptoms, 6.2 (1.0) vs 5.4 (1.4); emotions, 6.5 (0.8) vs 6.0 (1.0); and activities, 5.9 (1.4) vs 
5.0 (1.5). Factors such as male gender (odds ratio [OR], 0.60; 95% confi dence interval [CI], 0.41–0.87), being on immunotherapy (OR, 0.59; 
95% CI, 0.38–0.92), living in an urban environment (OR, 0.56; 0.33–0.93), and residing on the northern coast of Spain along the Bay of 
Biscay (OR, 0.56; 0.36-0.89) were independent protective factors against having a total PAQLQ score in the lower tertile. Conversely, being 
recruited in a primary care setting (OR, 1.55; 1.01–2.38) and having more severe asthma were risks for being in the lower tertile. 
Conclusions: Irrespective of the severity of the disease, season has a signifi cant infl uence on the HRQL of asthmatic children.
Key words: Asthma. Children. Immunotherapy. Quality of life. Seasons. 
■ Resumen
Objetivo: Saber cómo afectan las distintas estaciones del año a la calidad de vida (CV) de los niños asmáticos. 
Métodos: Cuatro grupos distintos de niños asmáticos de 7-14 años fueron reclutados por sus pediatras durante cada estación del año. Su CV 
se midió por medio del Paediatric Asthma Quality of Life Questionnaire (PAQLQ). Otros factores que se recogieron fueron: gravedad del asma, 
atopia, tratamiento médico, inmunoterapia, obesidad, hábito de fumar en los padres y medidas ambientales de control alergénico. 
Resultados: La puntuación general del PAQLQ (media ± DE) fue máxima en verano (6,2 ± 1,0) y mínima en otoño (5,5 ± 1,2). Esta misma tendencia 
se observó para la puntuación del dominio de síntomas (6,2 ± 1,0 vs. 5,4 ± 1,4), emociones (6,5 ± 0,8 vs. 6,0 ± 1,0) y actividades (5,9 ± 1,4 
vs. 5,0 ± 1,5). Determinados factores como el sexo masculino (OR, 95%IC, 0,60, 0,41-0,87), estar tratado con inmunoterapia (0,59, 0,38-0,92), 
vivir en un entorno rural (0,56, 0,33-0,93) y residir en la costa Cantábrica (0,56, 0,36-0,89), fueron protectores de manera independiente frente 
a encontrarse en el tercil inferior de la puntuación general del PQALQ. Al contrario, haber sido reclutado en un centro de atención primaria (1,55, 
1,61-3,67) y padecer un asma más grave fueron factores de riesgo de encontrarse en el tercil inferior de esta puntuación. 
Conclusiones: Independientemente de la gravedad de la enfermedad, la estación del año tiene una infl uencia signifi cativa en la CV de los 
niños asmáticos. 
Palabras clave: Asma. Niños. Inmunoterapia. Calidad de vida. Estaciones del año. 
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Introduction
Health-related quality of life (HRQL) has become an 
increasingly important issue in the management of asthma 
and it is now often used to evaluate the effectiveness of 
antiasthma drugs [1]; self-management, educational, and 
fi tness programs [2]; allergen avoidance measures [3]; or 
degree of specialization of the physician taking care of the 
asthmatic child [4]. As expected, HRQL is worse among 
asthmatic than among nonasthmatic children [5].
There are several specifi c questionnaires for estimating 
the HRQL of children with asthma, which can be answered 
either by the children themselves or by their parents. One of the 
most frequently used is the Paediatric Asthma Quality of Life 
Questionnaire (PAQLQ), which has shown good measurement 
properties, proving valid and able to discriminate [6]. It has 
been tested in children 7 to 17 years of age and minimal skills 
are needed for children to complete it correctly [7]. Moreover, 
this is the only HRQL questionnaire for asthmatic children that 
has been validated in Spanish [8].
Although the severity of asthma is a factor affecting 
HRQL [9], there seem to be other relevant factors. For example, 
in the study by Moy et al [10] in young adults, although lung 
function was not an independent predictor of HRQL at any 
level of asthma severity, shortness of breath was associated 
with HRQL at all levels. On the other hand, the use of rescue 
β-agonists predicted HRQL score only in the individuals with 
mild asthma. Thus, it seems that HRQL determinants vary 
according to asthma severity, at least in children. Furthermore, 
lung function improvements do not have a clear impact on 
changes in HRQL, at least in adults with persistent asthma [11]. 
HRQL measured by the Pediatric Allergic Disease Quality of 
Life Questionnaire is also affected by allergen exposure [12]. 
This questionnaire was developed to assess HRQL in the child 
with a multisystem allergic disease [13]. Furthermore, HRQL 
measured by the PAQLQ refl ects not only medical variables 
but also psychological factors [14].
Asthma severity can be much infl uenced by the environment 
(allergens, infections, air pollution, etc), which in turn can 
undergo dramatic seasonal changes in some countries: the 
visits of asthmatic children to emergency departments are 
most numerous during autumn and least numerous during 
summer [15]. Furthermore, asthma hospitalizations and deaths 
have clear seasonal variation [16-18]. Thus, it is of interest 
to know how seasonal variations can affect the HRQL of 
asthmatic children. The main aim of the present study is to 
evaluate how the HRQL of asthmatic children is affected by 
the season of the year and to know which additional factors 
can modify it.
Methods
Population
The asthmatic children (as diagnosed by their pediatricians) 
included in the present study were recruited in the clinics of 
primary care pediatricians, pediatric pulmonologists, and 
pediatric allergists. Each pediatrician evaluated the HRQL 
of the fi rst 3 asthmatic patients between 7 and 14 years of 
age attending for any reason at the beginning of each season, 
starting in autumn. After a prior training session in which 150 
pediatricians were instructed in how to administer the PAQLQ, 
recruitment period started. This period lasted for one month 
in each season: October 2003, January 2004, April 2004, and 
July 2004. The aim was to have a complete data set for at least 
300 children per season. Children were considered eligible to 
enter the study when their asthma was active, that is when they 
had had symptoms, had used short-acting β
2
-agonists, or had 
been on long-term antiasthmatic treatment during the previous 
year. The children’s parents or guardians were requested to give 
their written consent prior to enrolling a child in the study.
Measurements
HRQL was assessed with the validated Spanish version 
of the PAQLQ [8,19]. An additional questionnaire included 
demographic and environmental factors (pets, bedroom 
characteristics, smoking habits at home) and also questions 
on allergen reactivity (either by skin prick test or by allergen-
specifi c serum immunoglobulin E titer), asthma maintenance 
medication, and immunotherapy. Pediatricians were also asked 
to report the children’s asthma severity prior to treatment 
according to the Spanish guidelines for the management of 
pediatric asthma [20]. Those guidelines, which are similar to 
those of the Third International Pediatric Consensus Group’s 
statement on the treatment of childhood asthma [21], called 
for classifi cation as occasional episodic, frequent episodic, 
moderate persistent, and severe persistent.
Data Collection and Statistics
For a child’s data to enter the analysis, he or she had to 
meet the inclusion criteria and have completed the PAQLQ. 
Loss of 10% of the questionnaires due to incorrect completion 
was expected. For an α level of .05 and a power of 90% for 
contrast between 4 seasonal data sets, it was calculated that 308 
individuals per group would be necessary to detect a difference 
of 0.5 points, a fi gure assumed to be clinically signifi cant [22] 
in the PAQLQ score. A SD of 1.5 points was allowed.
Comparisons between the 4 seasons and also between the 
different asthma types were made by means of χ2 tests when 
variables were qualitative. When they were quantitative, the 
comparison was performed using Kruskal–Wallis analysis of 
variance for a single factor (either season or asthma severity). 
Calculations were made with SPSS software, version 12.0 
(Chicago, Illinois, USA). A logistic regression model was 
built using the PAQLQ score as the dependent variable 
and the following independent variables: gender, residence 
(rural, urban, intermediate), geographical area of residence 
(central plateau, Mediterranean coast, or northern coast along 
the Bay of Biscay [North Coast]), setting where the child 
received health care (primary care vs hospital outpatient 
clinic), sensitization (not sensitized or sensitized to mite, 
pollen, molds, or multiple allergens), season (autumn, winter, 
spring, summer), immunotherapy (yes, no), asthma severity 
(occasional episodic, frequent episodic, moderate persistent, 
severe persistent), inhaled corticosteroids (yes, no), pets (dog, 
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cat, hamster), preventive measures in the bedroom (antiallergy 
pillow, mattress covers) and smoking at home (any smoker vs 
no smoker). The fi rst tertile of the PAQLQ score was tested 
against the third tertile and factors with an odds ratio that was 
signifi cantly less than 1 were considered to be associated with 
a better PAQLQ score (protection against a lower HQRL). This 
logistic regression analysis was performed with the Intercooled 
Stata version 7 software (College Station, Texas, USA). The 
graphs of the global PAQLQ score and of the 3 different domains 
(symptoms, emotions, and activities) were drawn, according to 
asthma severity, with the Sigma Plot software package, version 
9.0 (Systat Software Inc, Erkrath, Germany). The signifi cance 
of the trend of the mean PAQLQ score from autumn to summer 
was estimated by means of the Cuzick test.
Results
The number of pediatricians who recruited children varied 
throughout the study period: 132 in autumn, 128 in winter, 89 
in spring and 74 in summer. This represents an approximate 
loss of 44% in recruiting pediatricians, although there was a 
certain turnover. The numbers of children with valid data (ie, 
who had complete information related to HRQL variables 
included and to allergy tests) were 352 in autumn, 339 in 
winter, 234 in spring and 178 in summer (total, 1103). A total 
of 658 children were excluded from the analysis because of 
missing variables. The demographic characteristics of the 
whole population and of each group of children in every season 
are shown in Table 1.
Table 1. Demographic Characteristics of the Participants* 
  Autumn, n=352 Winter, n=339 Spring, n=234 Summer, n=178 All Seasons, n=1103 
 
Age, y, mean (SD) 10.4 (2.0) 10.2 (2.0) 10.3 (2.1) 10.6 (2.1) 10.3 (2.0) 
Male gender 216 (62.6) 208 (62.3) 153 (65.9) 99 (56.3) 676 (62.2) 
Weight, kg 41.5 (12.8) 40.9 (13.0) 41.2 (13.3) 43.0 (13.6) 41.5 (13.1) 
Height, cm 144.5 (13.7) 143.2 (13.0) 143.4 (13.3) 145.4 (14.0) 144.0 (13.5)
Residence, n (%)      
 Rural 63 (18.7) 70 (21.1) 38 (16.7) 22 (12.9) 193 (18.1) 
 Intermediate 87 (25.8) 77 (23.3) 44 (19.4) 45 (26.5) 253 (23.8) 
 Urban 187 (55.5) 184 (55.6) 145 (63.9) 103 (60.6) 619 (58.1) 
Climatic zone      
 Plateau 182 (51.7) 165 (48.7) 109 (46.6) 89 (50.0) 545 (49.4) 
 Mediterranean, coastal 74 (21.0) 70 (20.6) 40 (17.1) 23 (12.9) 207 (18.8) 
 North Coast 96 (27.3) 104 (30.7) 85 (36.3) 66 (37.1) 351 (31.8) 
Type of Allergen      
 Mites 86 (24.4) 72 (21.2) 49 (20.9) 54 (30.3) 261 (23.7) 
 Pollen 31 (8.8) 29 (8.6) 21 (9.0) 30 (16.9) 111 (10.1) 
 Molds 13 (3.7) 12 (3.5) 8 (3.4) 5 (2.8) 38 (3.4) 
 Multiple 156 (44.3) 150 (44.2) 107 (45.7) 53 (29.8) 466 (42.2) 
Health care setting      
 Outpatient hospital clinic 93 (26.6) 88 (26.0) 67 (28.9) 52 (29.4) 300 (27.3) 
 Primary care clinic 257 (73.4) 250 (74.0) 165 (71.1) 125 (70.6) 797 (72.7) 
 Immunotherapy 261 (23.7) 106 (30.1) 74 (21.8) 41 (17.5) 40 (22.5) 
 Treatment with ICS 394 (35.7) 135 (38.4) 122 (36.0) 74 (31.6) 63 (35.4) 
Asthma severity      
 Infrequent episodic  121 (37.1) 143 (46.7) 105 (47.9) 68 (42.0) 437 (43.1) 
 Frequent episodic 123 (37.7) 97 (31.7) 71 (32.4) 71 (43.8) 362 (35.7) 
 Moderate persistent 78 (23.9) 60 (19.6) 41 (18.7) 23 (14.2) 202 (19.9) 
 Severe persistent 4 (1.2) 6 (2.0) 2 (0.9) 0 (0.0) 12 (1.2) 
Obesity 32 (9.7) 26 (8.3) 24 (10.8) 15 (8.8) 97 (9.3) 
Pets      
 Dog 56 (16.2) 61 (18.2) 36 (15.9) 33 (18.5) 186 (17.1) 
 Cat 22 (6.4%) 26 (7.8%) 11 (4.8%) 11 (6.2%) 70 (6.5%) 
Antiallergy covers           
 Pillow 69 (19.6%) 79 (23.3%) 59 (25.2%) 34 (19.1%) 241 (21.8%) 
 Mattress 87 (24.7%) 87 (25.7%) 63 (26.9%) 44 (24.7%) 281 (25.5%) 
Smoking at home 163 (46.8%) 156 (46.2%) 113 (48.3%) 78 (44.1%) 510 (46.5%) 
* Data are shown as number (%), except age, which is indicated as mean (SD). Because of missing values, the total sum of children in particular 
seasons might be less than the total number of children. North Coast indicates the zone along the Bay of Biscay; ICS, inhaled corticosteroids.
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There were statistically significant HQRL differences 
according to asthma severity both in the overall PAQLQ score and 
in the 3 domain scores (Table 2). The difference between scores 
of children with the mildest and the most severe asthma types 
was highest in the activities domain (1.4 points) and lowest in the 
emotional domain (0.7 points). The overall score difference was 
1.0 points, twice the amount considered clinically signifi cant.
The PAQLQ scores underwent statistically significant 
seasonal variation (Table 3). The overall score was worst in 
autumn (5.5 [1.2]) and best in summer (6.2 [1.0]). Again, the 
highest difference was in the activities domain (0.9 points). 
Those fi gures refer to the mean score for each season’s group, 
irrespective of the severity of their asthma. The seasonal changes 
of the PAQLQ score according to asthma severity are shown in 
the fi gure.
Girls had a slightly lower mean PAQLQ score than boys when 
the severity of asthma was not taken into account. The overall 
score for girls was 5.7 (1.2) points while for boys it was 5.9 (1.1) 
points (P = .006). In spite of girls’ lower scores in every strata, the 
only difference that was statistically signifi cant, and very close to 
being clinically signifi cant when the data was stratifi ed by asthma 
severity, was found between children with moderate persistent 
asthma (6.0 [1.1] for girls vs 5.7 [1.2] for boys, P = .01).
Children on immunotherapy had a better overall mean 
PAQLQ score than children who were not: 6.0 (1.1) vs 5.7 (1.2) 
(P = .002), considering the population as a whole. When the 
children were stratifi ed by asthma severity, the only signifi cant 
difference was between children with infrequent asthma (6.3 [1.0] 
on immunotherapy vs 6.0 [0.9] not on therapy, P = .012) 
although in the rest of the strata children on immunotherapy 
scored better. Among the sensitized children in the sample, 
those on immunotherapy again had a signifi cantly better overall 
PAQLQ score than those who were not, and the fi gures were 
equivalent to those obtained in the whole population (6.0 [1.0] on 
immunotherapy vs 5.7 [1.2] not on therapy, P = .009).
The highest tertile PAQLQ score cutoff points were 6.6, 6.9, 
and 6.4 for the symptoms, emotions, and activities domains, 
respectively, and 6.5 for the overall score. The corresponding 
fi gures for the lowest tertile were 5.2, 6.1, and 4.6 for the 3 
domains, respectively, and 5.4 for the overall score. The results 
of logistic regression are shown in Table 4. Male gender, 
immunotherapy and, to a lesser degree, urban residence, living on 
the North Coast, and being recruited in a hospital outpatient clinic 
were independently and signifi cantly associated with a higher 
PAQLQ score. As found in the univariate analysis, autumn was 
the worst season in terms of HRQL, while summer was the best; 
and the more severe the asthma the worse the HRQL.
Discussion
The results of the present study show that independent 
variables that affect HRQL along with asthma severity are male 
gender, seasonal variations, immunotherapy, urban residence, 
252
Table 2. Overall and Domain PAQLQ Scores According to Severity of Asthma*
  Domain  Overall
 Symptoms Emotional Activities  
Infrequent episodic  5.9 (1.2) 6.5 (0.8) 5.6 (1.4) 6.0 (1.0)
Frequent episodic  5.6 (1.3) 6.2 (0.9) 5.1 (1.5) 5.7 (1.1)
Moderate persistent 5.4 (1.3) 6.0 (1.1) 4.9 (1.5) 5.5 (1.2)
Severe persistent 4.7 (1.4) 5.8 (1.1) 4.2 (1.6) 5.0 (1.3)
P† <.001 <.001 <.001 <.001
*Data are shown as means (SD). PAQLQ indicates Paediatric Asthma Quality of Life Questionnaire.
† Analysis of variance. 
Table 3. Overall and Domain PAQLQ Scores by Seasons*
  Domain  Overall
 Symptoms Emotions Activities
Autumn 5.4 (1.4) 6.0 (1.1) 5.0 (1.5) 5.5 (1.2)
Winter 5.6 (1.3) 6.2 (0.9) 5.2 (1.5) 5.8 (1.1)
Spring 5.8 (1.2) 6.3 (0.9) 5.4 (1.5) 5.9 (1.0)
Summer 6.2 (1.0) 6.5 (0.8) 5.9 (1.4) 6.2 (1.0)
P† <.001 <.001 <.001 <.001
*Data are shown as means (SD). PAQLQ indicates Paediatric Asthma Quality of Life Questionnaire
† Analysis of variance. 
Seasons and Quality of Life in Asthmatic Children
 J Investig Allergol Clin Immunol 2007; Vol. 17(4): 249-256© 2007 Esmon Publicidad
living on the North Coast, and being recruited in a hospital 
outpatient clinic. This is not the fi rst study that has detected an 
infl uence of gender on the HRQL of asthmatic children measured 
by means of the PAQLQ. Warschburger et al [23] found that girls 
aged 8 to 16 years had a slightly lower HRQL than boys of the 
same age with the same degree of asthma severity attending an 
inpatient rehabilitation program. Previously, the same trend was 
observed in a group of individuals aged 16 to 34 years old [24]. 
This lower HRQL for females was not attributable to more severe 
disease as evidenced by lung function tests, but rather to a more 
severe subjective disease state in the females. The mean age of the 
children included in the present study (10.3 years) is a moment at 
which girls are much more aware of everything, and a possible 
hypothesis would be that this explains the observed difference in 
scores by gender. Although lung function was not measured in our 
study, the association of male gender with a better HRQL score is 
independent of the pediatrician-assessed severity of the disease. 
Being recruited in a primary care setting rather than in a 
hospital outpatient clinic was associated with HRQL in the lower 
tertile. This is most probably because mild or moderate asthma 
exacerbations are usually treated in the primary care setting and do 
not reach the hospital unless treated in the emergency department. 
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Table 4. Association Between the Studied Factors and the PAQLQ score*
  Domain  Overall
 
 Symptoms Emotions Activities  
Male gender 0.75 (0.52–1.07) 0.67 (0.48–0.94) 0.56 (0.39–0.81) 0.60 (0.41–0.87)
Residence     
 Rural 1 1 1 1   
 Intermediate 0.75 (0.42–1.34) 0.89 (0.52–1.54) 0.99 (0.56–1.74) 0.73 (0.41–1.32)
 Urban 0.64 (0.38–1.05) 0.65 (0.41–1.04) 0.68 (0.42–1.11) 0.56 (0.33–0.93)
Climatic Zone     
 Plateau 1 1 1 1 
 Mediterranean, coastal  0.86 (0.52–1.42) 1.17 (0.73–1.88) 0.99 (0.60–1.61) 0.97 (0.57–1.64)
 North Coast 0.57 (0.37–0.89) 0.61 (0.40–0.94) 0.60 (0.38–0.93) 0.56 (0.36–0.89)
Atopy     
 Nonatopic 1 1 1 1 
 Mite 0.77 (0.44–1.38) 1.15 (0.66–2.01) 0.84 (0.48–1.47) 0.75 (0.42–1.35)
 Pollen 0.64 (0.32–1.30) 0.98 (0.50–1.92) 0.61 (0.30–1.23) 0.62 (0.30–1.26)
 Molds 0.84 (0.33–2.18) 1.26 (0.47–3.40) 0.85 (0.34–2.16) 0.88 (0.33–2.33)
 Multiple 1.01 (0.60–1.67) 1.15 (0.71–1.86) 1.04 (0.63–1.71) 1.09 (0.65–1.83)
Season      
 Autumn 1 1 1 1 
 Winter 0.75 (0.49–1.15) 0.76 (0.51–1.16) 0.78 (0.50–1.22) 0.75 (0.47–1.17)
 Spring 0.57 (0.35–0.94) 0.68 (0.43–1.08) 0.60 (0.37–0.97) 0.63 (0.38–1.03)
 Summer 0.20 (0.11–0.35) 0.27 (0.15–0.46) 0.23 (0.13–0.41) 0.17 (0.09–0.32)
Health care setting     
 Hospital outpatient clinic 1 1 1 1 
 Primary care clinic 1.76 (1.16–2.69) 1.57 (1.06–2.31) 1.29 (0.86–1.94) 1.55 (1.01–2.38)
Inhaled corticosteroids 0.84 (0.58–1.23) 0.94 (0.66–1.34) 1.04 (0.73–1.51) 0.88 (0.60–1.29)
Immunotherapy 0.65 (0.42–0.98) 0.50 (0.33–0.75) 0.54 (0.35–0.83) 0.59 (0.38–0.92) 
Asthma severity     
 Occasional episodic 1 1 1 1 
 Frequent episodic 2.27 (1.51–3.39) 2.51 (1.71–3.70) 2.27 (1.53–3.37) 2.43 (1.61–3.67)
 Moderate persistent 2.88 (1.73–4.79) 2.67 (1.69–4.24) 2.60 (1.58–4.27) 2.90 (1.71–4.91)
 Severe persistent 9.24 (1.00–85.6) 5.96 (1.04–33.9) 9.96 (1.10–89.5) 9.03 (0.77–69.6)
Obesity 0.99 (0.53–1.87) 1.57 (0.88–2.81) 1.41 (0.77–2.56) 0.96 (1.00–85.5)
Pets at home     
 Dog 0.95 (0.57–1.59) 1.03 (0.65–1.62) 0.85 (0.52–1.39) 0.88 (0.52–1.51)
 Cat 0.85 (0.39–1.86) 0.83 (0.41–1.70) 0.80 (0.40–1.61) 0.76 (0.35–1.65)
Antiallergic covers     
 Pillow 1.02 (0.53–1.99) 0.89 (0.47–1.69) 0.78 (0.40–1.50) 0.82 (0.42–1.61)
 Mattress 0.71 (0.37–1.33) 1.08 (0.59–1.99) 1.03 (0.55–1.91) 0.88 (0.47–1.66)
Smoking at home 1.12 (0.78–1.61) 1.19 (0.85–1.66) 1.19 (0.83–1.70) 1.26 (0.87–1.82)
* Data are adjusted odds ratio (95% confi dence interval). North Coast indicates the zone along the Bay of Biscay.
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The asthmatic child recruited in a hospital outpatient clinic usually 
attends a scheduled visit. Furthermore, it should be emphasized 
that most children followed in hospital outpatient clinics also visit 
their primary care pediatricians, whereas not all asthmatic children 
followed in the primary care setting are seen in the hospital. Thus, 
the distinction between children visiting primary care or hospital 
outpatient clinics is not straightforward.
Seasonal variations of HRQL are not an unexpected fi nding: 
there are numerous studies showing that several markers of asthma 
severity are more frequent in certain seasons of the year. Quite 
recently, Silverman et al [15], in a large population of individuals 
attending emergency departments in New York City concluded 
that the highest number of visits occurred in the autumn and 
the lowest in the summer. Furthermore, seasonal fl uctuations in 
visits were highest in children aged 13 years or younger, with 
a peak occurring at approximately the age of 7 years. The so-
called September asthma epidemic has also been described in 
Canada and has been mainly related to respiratory viruses [18]. 
In Finland, Harju et al [16] described a double peak of hospital 
admissions for asthmatic children under the age of 15 years in 
spring and in autumn, probably refl ecting variations in trigger 
factors according to those authors. As the severity of the disease 
is the most important factor infl uencing HRQL among asthmatics, 
it is quite reasonable that they have a better HRQL when allergen 
contact and respiratory viral infections are less prevalent. In Spain, 
as in many other countries, the main allergen related to asthma 
in children is mite [25-27], so it is to be expected that the worst 
season in terms of HRQL measures would be autumn, when the 
environmental conditions for mites are best and when respiratory 
viral infections are also frequent. The same trend toward the best 
HRQL in summer and the worst in autumn was found for all 
asthma severity strata.
Another fi nding of the present study is the association between 
better HRQL and immunotherapy, in contrast with the apparent 
lack of effect of inhaled corticosteroids on the PAQLQ score. 
However, certain considerations should be taken into account. 
Firstly, asthma severity was classifi ed prior to the recruiting 
visit; that is, children had already been on treatment for months 
or years: it is quite possible that inhaled corticosteroids with or 
without other drugs had improved the disease previously. In other 
words, the effect of such treatment would have to have been tested 
against a group of children on placebo to conclude that inhaled 
corticosteroids do or do not have an impact on the HRQL of 
asthmatics, but numerous studies have shown this effect both in 
children and in caregivers [28,29]. Secondly, most uncontrolled 
children are put on inhaled corticosteroids regardless of whether 
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or not they are undergoing immunotherapy. The provision of 
immunotherapy in Spain depends on the pediatrician to whom 
the child is referred: most pediatric allergists use immunotherapy 
while most pediatric pulmonologists do not. The referral criteria 
vary widely between health areas and depend mainly on the local 
or regional health facilities. Thus, to a certain extent, the allocation 
to immunotherapy is random.
Immunotherapy, which could also have contributed to 
the enhancement of HRQL prior to recruitment by improving 
asthma, was independently associated with a better PAQLQ 
score. This association seems mostly attributable to the effect of 
immunotherapy on the less severe asthma forms and might be 
related to a better effect on the early stages of the disease [30-34]. 
It could also be hypothesized that children on immunotherapy 
are less vulnerable to the changes in allergen concentration in 
their environment. Thus, a more frequent adjustment of the 
corticosteroid dosage for children who are not on immunotherapy 
might be needed to maintain a more stable HRQL throughout 
the year. It is not likely that a selection bias would explain this 
fi nding (ie, that children on immunotherapy would have been 
selected from among the ones with a less severe asthma), as 
the severity of the disease is a factor included in the analysis. 
Another possible explanation is that children on immunotherapy 
are better assessed and more closely followed: this could in turn 
allow protective measures to be stricter and, therefore, more 
effective. It is not likely that children on immunotherapy were 
recruited when attending to receive a dose (a stable situation) 
while children not on it were recruited when they attended for an 
asthma exacerbation. Although this explanation cannot be totally 
ruled out, children attending to receive an immunotherapy shot are 
usually not seen by doctors but by nurses. It is also possible that 
the effect of immunotherapy is related more to the improvement 
of the rhinitis—which co-occurs with asthma in many allergic 
children—than to a better lung function, although it does not 
seem to be the case that it had any relationship with the HRQL 
of these children [10].
With respect to our fi nding of a lack of effect of inhaled 
corticosteroids, a type II error is always a possibility. That seems 
unlikely, however, as there does not seem to be any trend of effect 
of those drugs on HRQL, and the number of children is relatively 
high. A waning effect of inhaled corticosteroids, low compliance, 
spontaneous disease progression or a ceiling effect of those drugs 
on childhood asthma could be potential additional explanations.
Another unexpected fi nding is that urban, as opposed to 
rural, residence is independently associated with having an upper 
tertile PAQLQ score: urban children can probably attend medical 
facilities more easily and thus receive better care of their asthma. 
Furthermore, it was not anticipated that living along the North 
Coast would be associated with better HRQL. This is inconsistent 
with the fact that asthma is more prevalent and probably more 
severe in that area [35]. It is quite possible that precisely because 
of that, pediatricians there are better prepared to treat the disease 
more effectively.
The present study has an important limitation: there was 
no follow-up of the same children throughout the year. The 
data comes from different groups of children recruited in the 
different seasons. However, the large number of children in each 
group together with random selection probably overcomes this 
limitation.
In summary, the results of the present study suggest that 
independently of the severity of asthma, which could have been 
previously modifi ed by medical treatment, the HRQL of asthmatic 
children aged 7 to 14 years old is affected by seasonal variation, 
gender, immunotherapy and, to a lesser degree, urban residence 
and climatic zone. 
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